What is Pattern Bioscience?
Pattern Bioscience is a pioneering biotechnology firm specializing in rapid phenotypic identification and antimicrobial susceptibility testing. By utilizing innovative single-cell microbiology, the company delivers critical diagnostic results in hours rather than days, a significant improvement over conventional culture-based methods. This technological edge allows healthcare providers to make informed, data-driven decisions regarding antibiotic prescriptions, thereby improving patient outcomes and mitigating the rise of drug-resistant superbugs. The company's market position is defined by its commitment to disruptive innovation, targeting common infection sites to provide smarter, faster diagnostic solutions that are essential for modern healthcare infrastructure.
How much funding has Pattern Bioscience raised?
Pattern Bioscience has raised a total of $137.7M across 5 funding rounds:
Series A
$6.4M
Series B
$15.4M
Series C
$28.7M
Private Equity
$44.2M
Series D
$43M
Series A (2019): $6.4M, investors not publicly disclosed
Series B (2020): $15.4M led by Omnimed Capital and Illumina Ventures
Series C (2023): $28.7M supported by Daleshaw, Omnimed Capital, Antimicrobial Resistance Action Fund, and Illumina Ventures
Private Equity (2025): $44.2M, investors not publicly disclosed
Series D (2025): $43M backed by The AMR Action Fund and Illumina Ventures
Key Investors in Pattern Bioscience
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health.
The AMR Action Fund
The AMR Action Fund is dedicated to overcoming technical and funding barriers in antibiotic development, aiming to ensure a sustainable pipeline of new antibiotics to combat superbugs.
Omnimed Capital
Omnimed Capital is a specialized investment firm focused on supporting high-growth healthcare and medical technology companies.
What's next for Pattern Bioscience?
With the successful closure of its latest funding round, Pattern Bioscience is well-positioned to transition into a phase of accelerated commercial deployment and product refinement. The strategic focus will likely center on expanding the clinical utility of its diagnostic platform across diverse hospital environments and strengthening its regulatory footprint. As the company continues to scale, the integration of its technology into standard clinical workflows will be critical for establishing a new benchmark in infectious disease diagnostics. Investors remain optimistic that the firm's unique approach to phenotypic testing will not only drive significant market share but also play a vital role in the global effort to combat antimicrobial resistance through sustainable, high-impact innovation.
See full Pattern Bioscience company page
